Quality distributors include Bestbion company, who is responsible for distributing the cardiac biomarker in Germany and INyDIA for distribution in the competitive Spanish market.

In addition, Eurobio company will launch the assay in France, while Savas Medikal will unveil the product in Turkey.

Critical Diagnostics business development vice president Richard Hughes said, "Each has successfully launched new biomarkers in their respective markets, and believe, like us, that ST2 will be a critical new tool in the evolution of heart failure patient management."

Critical Diagnostics president James Snider said just recently, one of the hospitals in Barcelona established a protocol of using Presage ST2 assay as part of the standard of care for managing patients with heart failure.

"Ever more convincing clinical data is coming in on ST2’s value in prognosis and care of heart failure patients," Snider added.

"In these days of austerity, an assay that can actively improve patient outcomes while reducing overall health care costs is in great demand."